Yidu Technology's listing in Hong Kong skyrocketed

  News from our newspaper (Reporter Sun Qiru) Yesterday, Yidu Technology, which provides medical big data and artificial intelligence technology solutions, went public in Hong Kong. The opening skyrocketed 121.5% and the total market value was nearly 58.8 billion Hong Kong dollars.

The prospectus shows that from the 2018 fiscal year to the 2020 fiscal year, Yidu Technology recorded total revenue of 22.727 million yuan, 102 million yuan and 558 million yuan, respectively. The revenue growth rate in the past two years reached 348.9% and 447.1%.

Recently, AI medical unicorn company Hypothesis Technology has also reported that it plans to be listed on the Science and Technology Innovation Board.

  At the end of last year, my country's artificial intelligence medical enterprises entered a period of intensive harvest.

In early November, Shukun Technology's coronary CT angiography image vascular stenosis auxiliary triage software was approved; Guxiang Technology and United Imaging Intelligence followed closely and won the first "AI + lung nodules" registration certificate and the first one on the same day. "AI+Fracture" registration certificate.

One month later, Shenrui Medical also got its own "AI+Lung Nodules" certificate.

  After experiencing a downturn affected by the epidemic in the first half of the year, since the second half of 2020, capital has accelerated into the AI ​​medical field.

According to incomplete statistics, in 2020, AI Medical received a total of 47 financings, involving an amount of approximately 8.48 billion yuan, a year-on-year increase of 118%.

Kai-Fu Lee, chairman and CEO of Innovation Works, previously predicted that China will usher in a golden age of technology-driven industrial upgrading in the next ten years.

  With the gradual acceleration of AI in the medical industry, industry reshuffle and the Matthew effect began to appear.

According to a medical AI public financing list, the AI ​​medical market shows a clear head clustering effect.

Taking the medical imaging segment as an example, certified companies such as Sukun Technology and Keya Medical have received multiple financing within a year, while a large number of uncertified companies and emerging companies have difficulty obtaining capital support.

  It is worth noting that there is no mature profit model in the AI ​​medical market.

Many AI unicorns have not yet relied on their deployment in the AI ​​medical field to achieve profitability in the short term.

Take the Yidu Technology listed yesterday as an example. Despite its rapid revenue growth, Yidu Technology is still at a loss.

According to the company's prospectus, the corresponding net losses for the 2018-2020 fiscal year were 978 million, 934 million, and 1.511 billion; the net liabilities were 1.2 billion, 2.3 billion and 3.7 billion respectively.

  In addition, there are still some difficulties in the further development of the AI ​​medical industry. The 2020 China AI+ Medical Industry Research Report released by iResearch suggests that the widespread application of medical artificial intelligence has played an important role in improving medical quality and service efficiency, and reducing misdiagnosis and treatment. However, AI+ healthcare still has problems related to medical data, shortage of compound talents, lack of industry standards, and the long cycle of transforming medical research into mature products. Among them, data acquisition, use and data sharing are the biggest factors hindering the development of AI+medical.